Xolair (omalizumab) is a brand-name subcutaneous injection that’s prescribed for hives, asthma, and other conditions. This article covers topics such as side effects, dosage, and how Xolair works.

Kashiv Biosciences is currently developing subcutaneous and intravenous formulations of the injection ... a biosimilar to Xolair. The study enrolled 600 subjects worldwide and aims to assess ...

Asthma drug Xolair generated sales of CHF 2.5 billion ... s (a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) sales surged 62% year over year to CHF 1.7 billion.

According to the study, three treatment-emergent adverse events emerged as the most frequently reported, with each experienced by three individuals: injection ... of using both omalizumab and ...

It's worth noting that Ocrevus (around 2029), Tecentriq (2028), Perjeta (2027), Actemra (2024), Xolair (2024), Kadcyla ... (as it reduces the number of injections per annum patients require).

In other words, it is not food specific. Omalizumab is given as a shot under the skin (a subcutaneous injection). You’ll usually get it once every 2 to 4 weeks, with the first 3 doses given in the ...

A humanized monoclonal antibody directed to the high-affinity IgE-receptor (FcεRI)-binding domain of human IgE (omalizumab ... asthma when given by subcutaneous injection every 2–4 weeks ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.

Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is changing how certain asthma ...

It’s self-administered as a subcutaneous injection, either daily or three times a week. The newest DMTs are monoclonal antibodies. These treatments target specific molecules within the immune ...